RLYB
RLYB
NASDAQ · Biotechnology

Rallybio Corp

$8.22
-0.22 (-2.61%)
As of Mar 29, 10:35 PM ET ·
Financial Highlights (FY 2026)
Revenue
806.1K
Net Income
-8,435,973
Gross Margin
Profit Margin
-1,046.4%
Rev Growth
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 67.0% 67.0% 67.0%
Operating Margin -3,955.5% -14.2% -13.9% -13.2%
Profit Margin -1,046.4% -18.4% -19.0% -13.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 806.1K 116.64M 118.58M 115.83M
Gross Profit 78.15M 79.45M 77.61M
Operating Income -31,886,943 -16,609,242 -16,446,877 -15,292,701
Net Income -8,435,973 -21,434,773 -22,545,743 -15,491,219
Gross Margin 67.0% 67.0% 67.0%
Operating Margin -3,955.5% -14.2% -13.9% -13.2%
Profit Margin -1,046.4% -18.4% -19.0% -13.4%
Rev Growth -8.2% -9.4% -4.9%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 64.35M 70.31M 72.54M
Total Equity 151.82M 147.11M 145.93M
D/E Ratio 0.42 0.48 0.50
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -10,406,906 -23,823,087 -23,688,809 -21,137,696
Free Cash Flow -12,084,786 -12,382,292 -11,826,701